Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Nurses are vital experts to the multidisciplinary oncology team who continue to expand their role in meeting the needs of ...

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Advanced practice providers have the opportunity to instill hope in patients through education and personalized care.

An oral tablet formulation of zanubrutinib was approved for use in patients with certain lymphomas or leukemia and ...

Oncology nurses and APPs can help reduce discrimination faced by patients with cancer who are members of the LGBTQIA+ ...

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

Education before subcutaneous daratumumab administration can both reassure patients and reduce the occurrence of adverse ...

Toxicities related to Teliso-V are manageable for patients with c-Met overexpressing non-small cell lung cancer, according to ...

A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, ...

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a ...

Retifanlimab-dlwr (Zynyz) was granted approval from the FDA for treatment of locally recurrent or metastatic squamous cell ...